Healthcare company GRAIL Inc revealed on Monday the election of Matthew P. Young as its chief operating officer and chief financial officer with effect from 28 October 2019.
Most recently, Young has served as executive vice president and chief financial officer at Jazz Pharmaceuticals, a biopharmaceutical company.
Previously, Young has worked in investment banking at Barclays Capital Inc, Citigroup Global Markets Inc as well as Lehman Brothers Inc.
Currently, Young is a member of the board of PRA Health Sciences Inc's compensation and audit committee as well as lead independent director and chairman of the audit committee of CytomX Therapeutics Inc, a biopharmaceutical company.
GRAIL is focused on developing pioneering technology to for the early detection and identification of multiple deadly cancer types. The uses the power of next-generation sequencing, population-scale clinical studies and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test.
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories